Cancer Education
focusing on Specialized Topics of Interest

Taught by the Experts




www.BMLI.com
Overview Faculty & Disclsoure Agenda Sheraton Hotel Directions Registration
Live Simulcast Educational Needs Target Audience Learning Objectives CME/CE Credit Information
A CME/CE Accredited Satellite Symposium

Sheraton Chicago Hotel & Towers, 301 East North Water Street | Registration & Light Dinner 6:00 – 7:00 PM | Symposium 7:00 - 9:00 PM
This symposium is also being broadcast live as a Webcast via the Internet. Click here for simulcast registration only.
Integrating Immuno-Oncology Into Therapy for Lung Cancer: Challenging Patient Cases with Expert Panel Discussions
Overview Back to top
Co-Chairs: Drs. Frances A. Shepherd & Roy S. Herbst

Within the past three months the FDA has approved the first immune therapy for the treatment of lung cancer, an anti-PD-1 monoclonal antibody. Several other antibodies targeting PD-1 or its ligand are currently in clinical development for lung cancer. Immuno-Oncology is a very exciting and totally new class of anti-cancer therapy.

There are many important differences between immune therapy and the traditional, systemic approaches to treating NSCLC. These are the result of an entirely new mechanism of action involving the immune system’s checkpoint pathways that cause patient responses to immune therapy, as well as drug toxicity and toxicity management, to be much different than what occurs with targeted therapy or chemotherapy.

The objective of this two-hour symposium is to use five of the world’s leading medical oncologists from the US, Canada and the United Kingdom, who are experts on the use of Immuno-Oncology for lung cancer, to help medical oncologists and other healthcare professionals (HCPs) understand how Immuno-Oncology therapy can best be used to improve the outcome of their NSCLC patients in their practices today.

Two, highly interactive presentations have been carefully developed to help medical oncologists and other HCPs fully understand the vitally important differences in efficacy and toxicity with Immuno-Oncology therapy: the differences in efficacy/patterns of response to therapy, and the differences in toxicity/toxicity management with immune therapy. With these two interactive presentations, and with three carefully selected patient case studies, the participants in this symposium will interact with the expert faculty, by making treatment decisions and answering other important questions that are designed to help clinicians prepare to utilize this new Immuno-Oncology therapy for their patients.

Bring your own Smartphones and Tablets (iPad, Android, iPhone, Tablet): To help make this an enjoyable 2-hour learning experience the symposium will enable participants to use their own personal “smart devices” (smartphones and tablets). At the symposium each participant will use his/hers own smartphone or tablet and easily log into our private network to view all slides and ask and answer all questions of the faculty. These include treatment-related questions involving managing the very unique patterns of response to Immuno-Oncology therapy as well as questions involving the management and prevention of the unique toxicities associated with the use of anti-PD-1monoclonal antibodies for treating lung cancer, immune-related adverse events (irAEs).

In addition, the advantage to participants who bring their own smartphones or tablets is that they can download all slide presentations to their personal devices for use and access immediately following the symposium. There is no need to wait days or weeks for the slides. For those participants who do not bring their own smartphones/tablets we will provide iPads at the symposium. These will be available for the first 500 pre-registered participants of the symposium.

Due to the very high interest expected in this special symposium on Immuno-Oncology and lung cancer, taught by five experts, it is anticipated that registration will close before May 31, 2015 because it is expected that all of the seats in the symposium meeting room will be taken. Every effort will be made to accommodate as many participants as possible. Nevertheless, to guarentee a seat at this very special program we recommend that you register early. Thank you. We look forward to seeing you in Chicago and to your participation in this highly interactive and engaging program. Registration for the symposium is free, compliments of an unrestricted educational grant from Bristol-Myers Squibb. You can very easily register on this Website by clicking on the white-colored tab near the top of this page entitled "Free Registration" or by clicking on the white and blue-colored banner also located near the top of this page entitled, " Register Now Space is Limited: Sunday, May 31, 2015." You may register immediately.

Agenda Back to top
Sunday, May 31, 2015
6:00PM
Registration and Dinner  
7:00PM
Intro and CME/CE Pre-Test — Frances A. Shepherd, MD, FRCPC
7:05PM
Distinguishing Immuno-Oncology Therapy from a Chemotherapy & Targeted Therapy Model: The New Paradigm for NSCLC—An Interactive Presentation — Roy S. Herbst, MD, PhD
7:25PM
Expert Panel Discussion
7:35PM
Interactive CASE #1: Mild Progression After Initial Chemotherapy for Advanced Lung Adenocarcinoma: Change Treatment? — Frances A. Shepherd, MD, FRCPC
7:45PM
Expert Panel Discussion  
7:55PM
Interactive CASE #2: Squamous Cell NSCLC: Differentiating Between Progression and Pseudoprogression — David R. Spigel, MD
8:05PM
Expert Panel Discussion  
8:15PM
Interactive CASE #3: Treatment-Related Toxicity with Immune Checkpoint Inhibitor Therapy: Management vs. Discontinuation— Suresh S. Ramalingam, MD
8:25PM
Differences in Toxicities and Toxicity Management, Prevention Between Immuno-Oncology, Targeted and Chemotherapies—An Interactive Presentation — Mary E.R. O’Brien, MD, FRCP
8:45PM
Expert Panel Discussion and Audience Q&A  
8:55PM
CME/CE Post-Test — Roy S. Herbst, MD, PhD
9:00PM
Adjourn
This activity is being hosted in association with
Faculty & Disclosure Information Back to top
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Director, Thoracic Oncology Research Program
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT
USA

Consulting Fees: Genentech/Roche, Merck, Pfizer
Scientific Advisory Boards: Biothera, Diatech, Kolltan, N of 1
Clinical Trials Support / Grant: Genentech
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Frances A. Shepherd, MD, FRCPC
Professor of Medicine
Scott Taylor Chair in
Lung Cancer Research
University of Toronto
Princess Margaret Hospital
Toronto, Ontario
CANADA

Ownership Interest (stocks, stock options, or other ownership interest excluding diversified mutual funds): Eli Lilly, AstraZeneca
Honoraria: Eli Lilly, AstraZeneca, Bristol-Myers Squibb, Merck Serono, Roche/Genentech, Merck/Schering Plough, Boehringer Ingelheim
Consulting Fees: Eli Lilly, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Recombio, Synta Pharmaceuticals, Bristol-Myers Squibb
Research Funding: Boehringer Ingelheim

Mary E.R. O'Brien, MD, FRCP
Consultant Medical Oncologist
The Royal Marsden Hospital
Chair, European Organization for
Research and Treatment of Cancer (EORTC)
Lung Cancer Group
Sutton
UNITED KINGDOM

Consulting Fees: MSD

David R. Spigel, MD
Director, Lung Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, TN
USA

Other (Uncompensated Advisor): Genentech, Bristol-Myers Squibb


Suresh S. Ramalingam, MD
Professor of Hematology and Medical Oncology
Director, Division of Medical Oncology
Emory University
Winship Cancer Institute
Atlanta, GA
USA

Consulting Fees: Genentech, AstraZeneca, Bristol-Myers Squibb
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

LEAD NURSE PLANNER
Diane D. DePew, DSN, RN-BC

I have no real or apparent conflicts of interest to report.

PLANNER & CME/CE REVIEWER
Steve Madison, RPh, MBA (BMLI Manager)

I have no real or apparent conflicts of interest to report.

CME/CE PEER REVIEWER
Danielle Shafer, MD

I have no real or apparent conflicts of interest to report.

Supported by an Educational Grant from Bristol-Myers Squibb
Educational Needs Back to top

Lung cancer is a significant unmet medical need. It is the leading cause of cancer deaths in the US and in many other countries. In 2014, according to the American Cancer Society Facts and Figures there were an estimated 224,210 new cases, and 159,260 deaths from lung cancer. Survival rates vary depending upon the stage of the lung malignancy when it is diagnosed. Globally, the five-year survival rate for Stage I NSCLC is approximately 50 percent. For Stage IV NSCLC, the five-year survival rate is approximately two percent. Thus, it is clear that a significant unmet medical need exists for patients with lung cancer.

Despite the very high mortality occurring with lung malignancy there is cause to be optimistic because of a the recently FDA approved Immuno-Oncology monoclonal antibody targeting PD-1, the first immune therapy approved for lung cancer.

Because Immuno-Oncology is so different from traditional systemic therapy for lung cancer, targeted therapy and chemotherapy, a significant educational need exists to help medical oncologists and other healthcare professionals (HCPs) quickly understand how to utilize immunotherapy in their practices to help improve their lung cancer patients’ outcomes today.

Target Audience Back to top

This symposium is designed to meet the educational needs and help close the practice gaps of medical oncologists, hematologists, radiation oncologists, surgical oncologists, oncology nurses/nurse planners, oncology pharmacists and other HCPs involved in the treatment, care and management of patients with NSCLC. Today lung cancer is treated optimally by a multidisciplinary approach, thus, all of the aforementioned clinical specialties are invited to participate in this activity in Chicago on May 31, 2015 at the Sheraton Chicago Hotel and Towers. A map and directions to the Sheraton are located at the end of this Website, and can be found by clicking on the "Sheraton Hotel Directions" tab near the top of this Website.

Learning Objectives Back to top

The following learning objectives have been developed for this CME/CE symposium. Separate learning objectives have been developed for medical oncologists and other physicians as well as for oncology nurses and pharmacists because their roles in addressing the unmet medical needs of NSCLC patients are significantly different, especially because of the unique characteristics of Immuno-Oncology therapy.

PHYSICIANS
  1. Analyze the differences in how efficacy is measured when NSCLC treatment is Immuno-Oncology therapy versus traditional chemotherapy or targeted therapy.
  2. Compare and contrast the differences in Mechanisms of Action between Immuno-Oncology therapy and traditional targeted and chemotherapy for NSCLC.
  3. Critically assess the recent data using Immuno-Oncology therapy versus chemotherapy plus targeted therapy for second-line therapy of NSCLC.
  4. Evaluate the strategies for determining which NSCLC patients are candidates to receive Immuno-Oncology therapy versus treatment with traditional targeted or chemotherapy.
NURSES
  1. List the differences in how efficacy is measured when NSCLC treatment is Immuno-Oncology therapy versus traditional chemotherapy or targeted therapy.
  2. Recall the differences in Mechanisms of Action between Immuno-Oncology therapy and traditional targeted and chemotherapy for NSCLC.
  3. Critically assess the recent data using Immuno-Oncology therapy versus chemotherapy plus targeted therapy for second-line therapy of NSCLC.
  4. Describe the strategies for determining which NSCLC patients are candidates to receive Immuno-Oncology therapy versus treatment with traditional targeted or chemotherapy.
PHARMACISTS
  1. List the differences in how efficacy is measured when NSCLC treatment is Immuno-Oncology therapy versus traditional chemotherapy or targeted therapy.
  2. Recall the differences in Mechanisms of Action between Immuno-Oncology therapy and traditional targeted and chemotherapy for NSCLC.
  3. Critically assess the recent data using Immuno-Oncology therapy versus chemotherapy plus targeted therapy for second-line therapy of NSCLC.
  4. Describe the strategies for determining which NSCLC patients are candidates to receive Immuno-Oncology therapy versus treatment with traditional targeted or chemotherapy.
CME/CE Credit Information Back to top

Physicians

The BioMedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The BioMedical Learning Institute designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists

The BioMedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0838-0000-15-001-L01-P
Credits: 2 hours (0.2 ceu)
Type of Activity: Knowledge

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Nurses

The BioMedical Learning Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The BioMedical Learning Institute designates this educational activity for 2 contact hours.

Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Other

Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 2 hours of Category 1 credit for attending this symposium.

Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.

The Sheraton Chicago Hotel & Towers · Sheraton Ballroom Back to top

The Sheraton Chicago Hotel & Towers
Sheraton Ballroom
301 East North Water Street
Chicago, IL 60611-4300
Phone: 877-242-2558

Live Internet Simulcast Back to top

Attachments:

  1. Disclosure of Conflicts of Interest Form
  2. Program/Agenda
  3. Instructions for participation

The following are the instructions on how to participate in the symposium: “Integrating Immuno-Oncology Into Therapy for Lung Cancer.”  We hope you find this program highly educational and enjoyable.

Options for your participation in the Internet Simulcast
You have 2 ways to participate in this symposium via the Internet Simulcast. Either way will enable you to CME/CE credit.

  • Interactive: One involves interactive participation enabling you ask questions of the faculty just like the participants in the live meeting in Chicago, and to interact with the program and answer clinical and case study questions during each presentation.
  • Non-Interactive: The other way to participate is to watch and listen to the symposium without the ability to ask or answer questions.

If you choose interactive participation for the symposium you will need to have 2 separate internet browser windows open. One browser window is to view and hear the symposium presentations, and the other is to ask and answer questions during the symposium. Each browser window connects to a different Web Site.

You can do this any of a number of ways including having 2 browser windows open on one large computer screen or use your iPhone or iPad or other smart device as your second browser window to answer and ask questions and your computer browser window to view and listen to the symposium.

To connect to view and listen to the symposium in a non-interactive manner please click on the following Web Site hyperlink: http://www.idostream.com/events/05312015-2439/broadcast.php

To connect to the second Web Site which enables you to ask and answer questions please click on the following Web Site hyperlink with your other browser window or iPad, iPhone, etc.: https://bmli.cnf.io

Technical Requirements and Testing Your Connections 
It is highly recommended you test your connection(s) between 4:30PM to 6:00PM Central Time. Our system will be operational during this 90 minute time period which has been dedicated for testing and if you have any questions during this time please use the support chat feature (link is to the right of the Web Site -  http://www.idostream.com/events/05312015-2439/broadcast.php) or call the following telephone number: 1-800-382-1876

Minimum Requirements for the Live Internet Simulcast
PC Requirements
You need Windows XP Service Pack 2, Windows Vista, Windows 7 or Windows 8, and you'll need to use Internet Explorer or Firefox for your web browser. You should have at least a 1.2-gigahertz processor and 512 megabytes of RAM. Your Internet connection speed should be at least 1.5 Mbps.
Mac Requirements
You need an Intel-based computer with at least OS 10.4.11 and Firefox 3 or Safari 3. You'll also need at least 1 gigabyte of RAM. Your Internet connection speed should be at least 1.5 Mbps. The Microsoft Silverlight plug-in will be required (it is generally installed on most computers already). You can check here if you have it installed: https://www.microsoft.com/getsilverlight/Get-Started/Install/Default.aspx

Download Presentations After the Symposium
Presentations can be downloaded after the symposium due to some of the data being embargoed until it is presented. They can be downloaded here: http://www.bmli.com/asco2015

Faculty Disclosures of Conflicts of Interest
The attached document contains a list of faculty, BMLI staff members, and other healthcare professionals who have reported real or apparent conflicts of interest (COIs).  According to the ACCME, ACPE and ANCC, COIs are any "relevant financial relationships with commercial supporters" of this symposium.  For your information, all of the conflicts of interest have all been resolved through a rigorous ACCME, ACPE and ANCC-approved peer-review process prior to the symposium.  Please review this faculty disclosure COI document carefully prior to your participation in this symposium.

Symposium Sessions
The scientific sessions of the symposium on Sunday, May 31, 2015 are scheduled from at 7:00 p.m. to 9:00 p.m central time.  The agenda is contained in the enclosed attachment.

If for some reason you are unable to attend this Live Internet Simulcast the presentations from this symposium will be archived on the www.BMLI.com Web site in approximately 6 weeks for CME/CE credit. This will include a webcast of the event along with the downloadable slides and audio.

CME, CE Certificates, Certificates of Attendance and Completed Symposium Evaluation Forms
You will receive your CME or CE Certificate, or Certificate of Attendance approximately 4 to 6 weeks following the symposium. To receive any of these certificates, participants are required by the ACCME and ACPE to complete the Evaluation Form and then to submit the completed Evaluation Form using your iPad or smart device. To receive CE contact hour credit attendance at the entire activity and the successful completion of the post-test and evaluation form is required. By completing the Evaluation Form, participants are documenting their attendance and claiming their number of CME/CE credit hours. Fellows may complete a Certificate of Attendance for use in seeking CE credit in their States.

Attachments:

  1. Disclosure of Conflicts of Interest Form
  2. Program/Agenda
  3. Instructions for participation

Not an official event of the 2015 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or Conquer Cancer Foundation.